



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

cGAS-IN-3

Cat. No.:	HY-162459
Molecular Formula:	C ₂₁ H ₂₀ Cl ₂ F ₂ N ₄ O ₂
Molecular Weight:	469.31
Target:	Cyclic GMP-AMP Synthase
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	cGAS-IN-3 (compound 30d-S) is an orally active cyclic GMP-AMP synthase (Cyclic GMP-AMP Synthase/cGAS) inhibitor with good plasma exposure and low clearance. cGAS-IN-3 has anti-inflammatory activity and can significantly reduce lung inflammation in rats[1].br/[16][1].								
IC₅₀ & Target	cGAS ^[1]								
In Vitro	The inhibitory potency (IC ₅₀) of cGAS-IN-3 against cGAS in mouse RAW-Lucia cells is 2.87 μM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	cGAS-IN-3 (30 mg/kg; po; single dose) has preventive effects on LPS-induced acute lung injury (ALI) mouse model and can effectively reduce inflammation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>LPS-induced acute lung injury (ALI) mice model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>po; single dose and 0.5 h prior to ALI modeling; while ALI was induced by intratracheal instillation of 2 mg/kg LPS</td> </tr> <tr> <td>Result:</td> <td>Alleviated the severity of lung injury, presented by the ameliorated pathological changes Relieved pulmonary edema, and the reduced number of immune cells in BALF.</td> </tr> </table>	Animal Model:	LPS-induced acute lung injury (ALI) mice model ^[1]	Dosage:	30 mg/kg	Administration:	po; single dose and 0.5 h prior to ALI modeling; while ALI was induced by intratracheal instillation of 2 mg/kg LPS	Result:	Alleviated the severity of lung injury, presented by the ameliorated pathological changes Relieved pulmonary edema, and the reduced number of immune cells in BALF.
Animal Model:	LPS-induced acute lung injury (ALI) mice model ^[1]								
Dosage:	30 mg/kg								
Administration:	po; single dose and 0.5 h prior to ALI modeling; while ALI was induced by intratracheal instillation of 2 mg/kg LPS								
Result:	Alleviated the severity of lung injury, presented by the ameliorated pathological changes Relieved pulmonary edema, and the reduced number of immune cells in BALF.								

REFERENCES

[1]. Chen M, et al. Design, Synthesis, and Pharmacological Evaluation of Spiro[carbazole-3,3'-pyrrolidine] Derivatives as cGAS Inhibitors for Treatment of Acute Lung Injury. J Med Chem. 2024 Apr 25;67(8):6268-6291.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA